🧠AI AnalysisCibus Shifts to Direct Sales and Cost Cuts to Preserve Liquidity
Agricultural gene-editing firm Cibus is streamlining operations and prioritizing near-term commercial programs to reduce cash usage following its Q3 2026 update.
Topic: biotechnology
🧠AI Analysis🧠AI AnalysisFractyl Health Cuts 45% of Staff to Pursue Commercial Launch for Weight-Loss System
Fractyl Health is eliminating nearly half of its workforce and stopping gene therapy research to extend its operational funding. The corporate restructuring follows encou…
🧠AI AnalysisRelmada Therapeutics Outlines Financials and Business Updates in Third-Quarter 2026 Call
Relmada Therapeutics reviewed its financial results and corporate progress for the third quarter of 2026 during an earnings conference call led by CEO Sergio Traversa and…
🧠AI AnalysisCuris Outlines Q3 2026 Progress in Lead Lymphoma Clinical Program
Curis, Inc. hosted its third-quarter 2026 corporate update, reporting steady advancement in its lead primary central nervous system lymphoma program within the TakeAim Ly…